Similar results were obtained with multivariate linear analyses performed Epigenetics inhibitor using VAS and Utility-index. DC, HCC,

AIH and LTL reported the highest decrease in VAS and Utility score. In conclusion, our results show that HRQoL of asymptomatic liver conditions are comparable to the general population except for the Anxiety/depression dimension. The HRQoL decreased in advanced LDs (DC, HCC, LTL) and AIH. This study provides an actual true estimate of the impact of major LDs on the patients’ HRQoL compare to the general population, and therefore is a key tool for decision-making in care delivery for liver diseases. Disclosures: Lorenzo G. Mantovani – Advisory Committees or Review Panels: Bayer; Grant/ Research Support: Jansen, Merck and Co; Speaking and Teaching: Bayer The following people have nothing to disclose: Paolo A. Cortesi, Matteo Rota,

Luciana Scalone, Paolo Cozzolino, Giancarlo Cesana, Stefano Okolicsanyi, Antonio Ciaccio, Marta Gemma, Stefano Fagiuoli, Maria G. Valsecchi, Luca S Belli, Mario Strazzabosco Introduction: Chronic liver disease (CLD), similar to congestive heart failure (CHF) and chronic obstructive pulmonary disease (COPD), represents end-stage damage to a major vital organ. However, its relative disease burden compared to these other common chronic conditions has not been well Sunitinib chemical structure characterized. Methods: We examined all CLD, CHF and COPD related encounters (2004-2013) across the largest healthcare system in Dallas-Fort Worth (8 hospitals, catchment area of 7 million, >130,000 annual admissions). We also included secondary admissions (e.g. renal failure or infection) in persons with underlying chronic diseases to reduce ascertainment

bias. We compared demographics, the median length of stay (LOS), ICU utilization, readmission rates, cost per admission and temporal trends for patients with CLD versus those with CHF and COPD. Results:There were 26,816 CLD related, 60,415 CHF related and 34,199 Adenylyl cyclase COPD related admissions. As compared to the other chronic diseases, CLD patients were younger, more likely to be uninsured or have Medicaid.(Table) The median LOS, ICU utilization, and direct costs were higher for CLD admissions as compared to CHF; while median LOS was less than for COPD, CLD ICU utilization and direct costs were still higher. Readmission rates (30d) were also higher for CLD (20.5%) as compared to other chronic diseases (17.5% CHF and 17.9% COPD, p<0.01). Between 2004 and 2013, there was almost a two fold increase (82%) in CLD admissions (1,288 vs. 2,348/100,000) with a disproportionate increase in median cost per encounter. In contrast, admissions for CHF (3,855 vs. 4,122/100,000) and COPD (1,779 vs. 2,654/100,000) increased by 6% and 49%, respectively. A significant portion of the increase in CLD admissions was driven by hospitaliza-tions for elderly patients: admission rates for CLD patients > 65 years increased by 92% (874 vs. 1679/100,000) as compared to CHF (0%) and COPD (31%).